Nuveen
DERM icon

Nuveen’s Journey Medical DERM Stock Holding History

Nuveen’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,034
Closed -$113K – 3768
2026
Q1 		$113K Buy
24,034
+8,324
+53% +$64.6K ﹤0.01% 3170
2025
Q4 		$121K Hold
15,710
– – ﹤0.01% 3200
2025
Q3 		$112K Hold
15,710
– – ﹤0.01% 3216
2025
Q2 		$113K Buy
+15,710
New +$109K ﹤0.01% 3241

Other funds holding DERM

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAIM
Punch & Associates Investment Management Edina, Minnesota $2.02B AUM 40.6% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.41B AUM 25.22% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Nuveen's DERM Position: Q2 2026 in Review

Nuveen sold out of Journey Medical (DERM) in Q2 2026, closing a stake of 24,034 shares — an estimated $113K sold.

Nuveen first reported a position in DERM in Q2 2025 and held it in 4 quarters. The position peaked at $121K in Q4 2025. 71 funds tracked by Wall St. Rank hold DERM as of Q2 2026.

  • Nuveen reported no remaining Journey Medical position as of Q2 2026 after selling out during the quarter.
  • Nuveen sold 24,034 Journey Medical shares in Q2 2026, an estimated $113K.
  • Nuveen first reported a position in Journey Medical in Q2 2025 and held it in 4 quarters.
  • Nuveen's Journey Medical position peaked at $121K in Q4 2025.
  • 71 funds tracked by Wall St. Rank held Journey Medical as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.